Sarepta Therapeutics, financials
$18.64−0.85%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.20B | $1.90B | $1.24B | $933.0M | $701.9M | $540.1M | $380.8M | $301.0M | $154.6M | $5.4M |
| Gross profit | $1.36B | $1.58B | $1.09B | $793.0M | $604.8M | $476.7M | $324.2M | $266.8M | $147.2M | $5.3M |
| Gross margin | 61.8% | 83.2% | 87.9% | 85.0% | 86.2% | 88.3% | 85.1% | 88.6% | 95.2% | 98.1% |
| Operating income | -$699.8M | $218.1M | -$267.8M | -$536.2M | -$459.7M | -$564.2M | -$705.6M | -$343.6M | -$171.6M | -$266.7M |
| Net income | -$713.4M | $235.2M | -$536.0M | -$703.5M | -$418.8M | -$554.1M | -$715.1M | -$361.9M | -$50.7M | -$267.3M |
| Net margin | −32.5% | 12.4% | −43.1% | −75.4% | −59.7% | −102.6% | −187.8% | −120.2% | −32.8% | −4930.2% |
| Diluted EPS | $-7.13 | $2.34 | $-5.80 | $-8.03 | $-5.15 | $-7.11 | $-9.71 | $-5.46 | $-0.86 | $-5.49 |
| EBITDA | -$613.3M | $255.8M | -$223.4M | -$494.3M | -$421.7M | -$537.3M | -$671.1M | -$331.4M | -$135.1M | -$261.1M |
| Operating cash flow | -$205.5M | -$205.8M | -$501.0M | -$325.3M | -$443.2M | $107.5M | -$456.5M | -$388.7M | -$232.0M | -$245.8M |
| Free cash flow | -$307.5M | -$342.7M | -$577.1M | -$356.2M | -$481.7M | $25.3M | -$516.1M | -$449.8M | -$244.0M | -$251.2M |
| Diluted shares | 100.1M | 107.9M | 92.4M | 87.6M | 81.3M | 78.0M | 73.6M | 66.3M | 58.8M | 48.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $801.3M | $1.10B | $428.4M | $966.8M | $2.12B | $1.50B |
| Short-term investments | $138.4M | $251.8M | $1.25B | $1.02B | $0.00 | $435.9M |
| Total debt | $829.0M | $1.14B | $1.24B | $1.54B | $1.10B | $992.5M |
| Total assets | $3.35B | $3.96B | $3.26B | $3.13B | $3.15B | $2.98B |
| Total liabilities | $2.21B | $2.44B | $2.41B | $2.74B | $2.22B | $2.22B |
| Shareholders' equity | $1.14B | $1.53B | $859.3M | $384.9M | $928.0M | $761.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology